We uniquely bring together supercomputing power, our proven causal AI reverse-engineering engine, and our collaborators’ massive patient multiomics and outcome datasets to build Gemini Digital Twins, in silico models of human disease that drive knowledge-based discovery and development across the biopharma pipeline.
Understanding the molecular interactions that cause diseases reveals a set of novel potential intervention points. These findings can be used by our biopharma partners to discover new and highly targeted drugs that can prevent further development of – or even reverse – disease processes.
Aitia’s causal AI-based knowledge discovery engine is leading to differentiated and novel partnered programs across multiple diseases with high unmet medical need.
We bring our technology, data, and expertise in generating biological knowledge and join it with our partner’s own data and pharmaceutical R&D expertise to accelerate the discovery and development of new therapies for multiple areas of unmet medical need, e.g., oncology, neuro-degeneration, immunological, and cardiometabolic diseases.
